Format

Send to

Choose Destination
Expert Opin Investig Drugs. 2012 Apr;21(4):515-22. doi: 10.1517/13543784.2012.660250. Epub 2012 Feb 13.

Tedizolid (TR-701): a new oxazolidinone with enhanced potency.

Author information

1
American University of Beirut Medical Center, Beirut, Lebanon. zk10@aub.edu.lb

Abstract

INTRODUCTION:

Tedizolid phosphate (TR-701) is a new oxazolidinone prodrug that is transformed in the serum into the active drug tedizolid (TR-700). Tedizolid acts by inhibiting protein synthesis and has broad activity against Gram-positive pathogens, including strains that are resistant to linezolid.

AREAS COVERED:

This review summarizes the currently available data on this new antimicrobial agent. In vitro activity, pharmacokinetics/pharmacodynamics, clinical efficacy and safety are all addressed.

EXPERT OPINION:

Tedizolid will provide a useful addition to the antimicrobial armamentarium, particularly in complicated skin and skin structure infections, due to its high oral bioavailability and once-daily dosing. The results of future studies will serve to better position tedizolid among the newly approved agents for infections caused by Gram-positive organisms.

PMID:
22324973
DOI:
10.1517/13543784.2012.660250
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center